The oral tablet formulation was approved for adults with weakened immune systems who have not responded to other therapy.
Commentary|Videos|May 19, 2026
2026 Hantavirus Outbreak: The Current Situation
Author(s)Brian Nowosielski, Jeffery Goad, PharmD, MPH
Jeffery Goad, PharmD, MPH, president of the National Foundation for Infectious Diseases, provided his expert perspectives on the ongoing hantavirus outbreak.
Advertisement
Advertisement
A hantavirus outbreak aboard the MV Hondius cruise ship has put public health officials and pharmacists on alert. Although experts are urging calm, they are also calling on pharmacy professionals to stay vigilant as the situation continues to unfold.
Related to this article
The novel tool can be used to inform vaccine policy, monitor impact, and essentially strengthen overall surveillance.
Infectious disease readiness depends on rehearsed workflows, bidirectional public health communication, and rapid access to care.
Therapy is aimed at decreasing pathogenic IgA production and immune complex formation as well as managing the effects of existing nephron loss.
Harini Bupathi, Esq, joins to discuss the impacts of PBM network terminations and how pharmacies can recover financially.
Pharmacists expand access with no-appointment care but face state laws limiting test-to-treat for COVID-19 and flu, fueling calls for advocacy.
AJ Barbarito, Esq, provides nuance to the evolving pharmacy reimbursement landscape and how PBMs and pharmacies alike are adapting as they approach 2027.
Nicole Pezzino, PharmD, BCACP, BC-ADM, CDCES, details how pharmacies can utilize the booming GLP-1 medication class for greater revenue opportunities.
Advertisement
Advertisement